Department of Surgery, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, #600, Yishan Road, Shanghai, 200233, China.
Department of Surgery, Heilongjiang Provincial Hospital Affiliated to Harbin Institute of Technology, #82, Zhongshan Road, Harbin, 1500036, China.
World J Surg Oncol. 2022 Jun 21;20(1):210. doi: 10.1186/s12957-022-02658-3.
The risk of HCC is documented to be age-related. The outcomes of young HCC patients on postoperative prognosis are not well understood. The study aims to compare the characteristic differences between adolescent and young (AYA) and non-AYA HCC patients.
We performed a retrospective analysis of the clinical and pathological findings and the survival of 243 HCC patients who underwent operations between 2007 and 2018.
The AYA group had a higher AFP level and a higher prevalence of family history of HCC or other cancers than the non-AYA group (P < 0.01 and P < 0.05). AYA patients had more unfavorable pathological characteristics including bigger lesion size, microvascular invasion, portal vein invasion, and hepatic capsule invasion. They also had a more unfavorable Edmondson grade and less tumor capsule formation (P < 0.01). Age was an independent predictor of survival in HCC patients. AYA patients had poorer disease-free and overall survival than non-AYA patients did (P < 0.01). Patients under 30 years old had an even poorer disease-free survival than those aged 30-40 (P = 0.047).
AYA patients exhibited a higher recurrence rate and disease-related death rate with more unfavorable pathological characteristics. Enhanced follow-up for young HCC patients should be applied.
肝癌的风险与年龄有关。年轻肝癌患者术后预后的结果尚不清楚。本研究旨在比较青少年和年轻(AYA)与非 AYA 肝癌患者的特征差异。
我们对 2007 年至 2018 年间接受手术的 243 例肝癌患者的临床和病理发现及生存情况进行了回顾性分析。
AYA 组的 AFP 水平较高,肝癌或其他癌症家族史的发生率高于非 AYA 组(P < 0.01 和 P < 0.05)。AYA 患者具有更不利的病理特征,包括更大的病变大小、微血管侵犯、门静脉侵犯和肝包膜侵犯。他们还具有更差的 Edmondson 分级和更少的肿瘤包膜形成(P < 0.01)。年龄是肝癌患者生存的独立预测因素。AYA 患者的无病生存率和总生存率均低于非 AYA 患者(P < 0.01)。30 岁以下患者的无病生存率甚至比 30-40 岁患者更差(P = 0.047)。
AYA 患者表现出更高的复发率和疾病相关死亡率,且具有更不利的病理特征。应加强对年轻肝癌患者的随访。